Search Results 131-140 of 18173 for creatine evidence

1. Steroid dosage risks and benefits when managing lupus nephritis - Mayo Clinic News Network

   "Steroids have been used for 75 years, but there was minimal evidence about dosing," says Dr. Duarte García. "This research provides information to help ...

2. Testing The Use Of Ado-Trastuzumab Emtansine Compared To The Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) For Recurrent, Metastatic, Or Unresectable HER2-Positive Salivary Gland Cancer - Mayo Clinic

   - For patients with known evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if ...

3. Pazopanib in Treating Patients with Metastatic Non-Clear Cell Kidney Cancer - Mayo Clinic

   Subjects using HRT must have experienced total cessation of menses for ≥ 1 year and be greater than 45 years of age OR have had documented evidence of ...

4. EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx - Mayo Clinic

   ... creatinine clearance <50 mL/min calculated by the Cockroft Gault method, eventually confirmed by measured creatinine ... evidence of recurrence. Patients who have ...

5. Early Feasibility Study - Transcatheter Atrial Shunt System - Mayo Clinic

   Has renal insufficiency as determined by creatinine ... Echocardiographic or clinical evidence of congestive hepatopathy. ... Echocardiographic or clinical evidence ...

6. Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia - Mayo Clinic

   ... evidence of infection. Patients with Classic Hairy Cell Leukemia may receive ... Creatinine ≤ 2.0 mg/dL, and/or. Creatinine clearance (estimated GFR [Cockcroft- ...

7. Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   - Patients must have evidence of adequate renal function, as defined by the following: creatinine clearance (CrCl) >= 30 mL/min., as measured by a 24-hour ...

8. A Study to Compare Standard-Dose Combination Chemotherapy with High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Resistant Germ Cell Tumors - Mayo Clinic

   Evidence of Disease. Must have evidence of progressive or recurrent GCT (measurable or non-measurable) following one line of cisplatin-based chemotherapy ...

9. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors - Mayo Clinic

   Creatinine clearance or radioisotope GFR ≥70 mL/min/1.73 m2 or a serum creatinine based on age/gender as follows: ... evidence of resolving hemorrhage will be ...

10. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors - Mayo Clinic

    Renal function: must have a creatinine clearance ≥ 60 mL/min (CockcroftGault equation); ... evidence of new or enlarging brain metastases ... Subject has any ...